[Skip to Navigation]
Comment & Response
April 25, 2019

Notice of Retraction and Replacement. Choi et al. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study. JAMA Oncol. 2019;5(1):30-36

Author Affiliations
  • 1Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
  • 2Division for Healthcare Technology Assessment Research, National Evidence-Based Healthcare Collaborating Agency, Seoul, Republic of Korea
JAMA Oncol. 2019;5(6):913-914. doi:10.1001/jamaoncol.2019.0576

To the Editor On behalf of our coauthors, we write to report serious errors in our article, “Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study,” published online on September 27, 2018, and in the January 2019 issue of JAMA Oncology.1

This article reports a study that compared the risk of hepatocellular carcinoma (HCC) and mortality or liver transplant in patients with chronic hepatitis B infection who were treated with entecavir or tenofovir. The study evaluated a Korean nationwide population-based cohort of 24 156 patients who were treatment-naive adults and a validation cohort of 2701 hospital patients who had been treated with entecavir or tenofovir. The nationwide cohort data were retrieved from January 1, 2010, to December 31, 2016, and the hospital cohort data were gathered from January 1, 2010, to October 31, 2017. We concluded that tenofovir treatment was associated with a significantly lower risk of HCC and mortality or transplant compared with entecavir treatment.